13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001524362
Total reported value
—
$207.5M
10 檔
70.3%
The Q4 2024 SEC filing reveals that Indaba Capital Management, L.P. held a total portfolio value of $207.5M, covering 10 public equity positions.
In Q4 2024, Indaba Capital Management, L.P. displayed an active expansion posture, initiating 4 new positions and adding to 4 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OBDC | Blue Owl Capital Corporation | Stock-Financials | 19.41% | — | — | |
| 2 | BAND 0.5 04-01-28Bond | Bandwidth Inc | Bond | 15.50% | — | — | |
| 3 | ONTF | On24 Inc | Stock-Other | 13.20% | — | — | |
| 4 | RVNC 1.75 02-15-27Bond | Revance Therapeutics Inc | Bond | 11.58% | — | — | |
| 5 | INN 1.5 02-15-26Bond | Summit Hotel Properties | Bond | 10.58% | — | +403.64% | |
| 6 | HP5A | Equity Commonwealth | Stock-Other | 8.14% | — | +103.19% | |
| 7 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | Bond | 6.28% | — | +55.56% | |
| 8 | TVTX 2.5 09-15-25Bond | Travere Therapeutics Inc | Bond | 6.18% | — | — | |
| 9 | AXDX 5 12-15-26Bond | Accelerate Diagnostics | Bond | 5.95% | — | +2.50% | |
| 10 | ESPR | Esperion Therapeutics Inc | Stock-Other | 3.18% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OBDC | Blue Owl Capital Corporation | +19.4% | NEW | New buy |
| 2 | RVNC 1.75 02-15-27Bond | Revance Therapeutics Inc | +11.6% | NEW | New buy |
| 3 | INN 1.5 02-15-26Bond | Summit Hotel Properties | +8.8% | +403.64% | Add |
| 4 | TVTX 2.5 09-15-25Bond | Travere Therapeutics Inc | +6.2% | NEW | New buy |
| 5 | ESPR | Esperion Therapeutics Inc | +3.2% | NEW | New buy |
| 6 | IRWD 1.5 06-15-26Bond | Ironwood Pharmaceuticals | +2.9% | +55.56% | Add |
| 7 | ONTF | On24 Inc | +2.1% | — | Unchanged |
| 8 | BAND 0.5 04-01-28Bond | Bandwidth Inc | +2.1% | — | Unchanged |
| 9 | AXDX 5 12-15-26Bond | Accelerate Diagnostics | +0.6% | +2.50% | Add |
| 10 | LAB 5.25 12-01-24Bond | Standard Biotools Inc | -3.3% | EXIT | Sold out |
| 11 | XMTR 1 02-01-27Bond | Xometry Inc | -7.9% | EXIT | Sold out |
| 12 | ESPR 4 11-15-25Bond | Esperion Therapeutics | -13.7% | EXIT | Sold out |
| 13 | HP5A | Equity Commonwealth | -31.9% | +103.19% | Add |
According to official SEC Form 13F filings, Indaba Capital Management, L.P. reported a total U.S. public equity portfolio value of $207.5M across 10 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OBDC, BAND 0.5 04-01-28, ONTF) accounted for 70.3% of total reported equity market value during Q4 2024.
Top New Position Initiated
OBDC
市值: $40.3M
Top Position Liquidated / Trimmed
ESPR 4 11-15-25
前期市值: $32.0M
During Q4 2024, Indaba Capital Management, L.P.'s top holdings by market value included OBDC (19.4%)、BAND 0.5 04-01-28 (15.5%)、ONTF (13.2%). The largest single position, OBDC, represented 19.4% of total portfolio value.
In Q4 2024, Indaba Capital Management, L.P. made 11 total portfolio adjustments, initiating 4 new buys, adding to 4 positions, trimming 0 holdings, and fully liquidating 3 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.